Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting ...

Pfizer’s vaccine – called Abrysvo – is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older, the same label that the FDA gave to ...

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...